Neuronal Plasticity and Signaling in Neuropathic Pain
神经病理性疼痛中的神经元可塑性和信号传导
基本信息
- 批准号:8839310
- 负责人:
- 金额:$ 35.52万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-03-15 至 2016-08-28
- 项目状态:已结题
- 来源:
- 关键词:Adverse effectsAnalgesicsAnimal ModelBiochemical GeneticsCalcineurinCalcineurin inhibitorClinicalControl GroupsDevelopmentDrug usageGenetic TechniquesGlutamatesGoalsGraft RejectionHealthImmunosuppressive AgentsLeadMaintenanceMediatingMolecularN-Methyl-D-Aspartate ReceptorsN-MethylaspartateNMDA receptor A1NR1 geneNeuronal PlasticityNociceptionOperative Surgical ProceduresOrgan TransplantationPatientsPeripheral nerve injuryPhosphorylationPhosphorylation SitePilot ProjectsPlayPosterior Horn CellsProtein phosphataseProteinsRattusRegulationResistanceRoleSerineSignal TransductionSiteSpinalSpinal CordSynapsesSynaptic TransmissionSynaptic plasticitySyndromeTestingThreonineTissuesTraumatic Nerve Injuryallodyniaattenuationcasein kinase IIcentral sensitizationchronic neuropathic paindorsal hornimprovedinterdisciplinary approachnerve injuryneurotransmissionnovel strategiespainful neuropathypostsynapticpreventreceptor functiontransmission processtreatment strategy
项目摘要
DESCRIPTION (provided by applicant): Neuronal Plasticity and Signaling in Neuropathic Pain Project Summary Activity-dependent synaptic plasticity at the spinal cord level is fundamentally important to the development of neuropathic pain caused by traumatic nerve injury and surgery. N-methyl-D-aspartate (NMDA) receptors in the spinal dorsal horn are critically involved in central sensitization and maintenance of neuropathic pain. However, the mechanisms of potentiated NMDA receptor activity in the spinal cord after nerve injury remain poorly understood. Although increased phosphorylation of NMDA receptors after nerve injury is known, the upstream mechanisms of increased NMDA receptor activity in neuropathic pain remain to be determined. In our preliminary studies, we found that inhibition of the protein kinase CK2 in the spinal cord completely reversed increased NMDA receptor activity and produced long-lasting attenuation of allodynia caused by nerve injury. In this application, we will use an animal model of neuropathic pain to test the central hypothesis that nerve injury increases CK2 activity in the spinal cord, which facilitates phosphorylation of the NR1 subunit of NMDA receptors and potentiates NMDA-mediated synaptic transmission in neuropathic pain. The specific aims of this application are to (1) define the role of imbalance between the CK2(phosphorylation) and calcineurin(de-phosphorylation) activities in augmented NMDA-mediated synaptic transmission at the spinal cord level and neuropathic pain; (2) determine the level of CK2 activity and its role in increased phosphorylation of the NR1 subunit of NMDA receptors in the spinal cord after nerve injury; and (3) identify the protein interaction between NR1 and CK2 subunits, the CK2 phosphorylation sites on the NMDA receptor, and their roles in regulation of increased NMDA receptor activity in neuropathic pain. The role of CK2 in the development of synaptic plasticity in the spinal cord induced by nerve injury has not been recognized previously. We expect that new findings from this proposal will be critical not only to the significant improvement of our understanding of the molecular mechanisms of neuropathic pain but also to the development of new strategies to treat neuropathic pain. Because directly blocking NMDA receptors produces intolerable side effects, targeting CK2 and its specific NMDA receptor phosphorylation sites could represent novel strategies for reducing the NMDA receptor activity and neuropathic pain.
描述(由申请人提供):神经性疼痛中的神经可塑性和信号传导项目概述脊髓水平的活动依赖性突触可塑性对于由创伤性神经损伤和手术引起的神经性疼痛的发展至关重要。脊髓背角的N-甲基-D-天冬氨酸(NMDA)受体在神经病理性疼痛的中枢致敏和维持中起重要作用。然而,神经损伤后脊髓中NMDA受体活性增强的机制仍然知之甚少。虽然已知神经损伤后NMDA受体磷酸化增加,但神经病理性疼痛中NMDA受体活性增加的上游机制仍有待确定。在我们的初步研究中,我们发现抑制脊髓中的蛋白激酶CK 2完全逆转了NMDA受体活性的增加,并产生了神经损伤引起的异常性疼痛的持久衰减。在本申请中,我们将使用神经性疼痛的动物模型来测试神经损伤增加脊髓中的CK 2活性的中心假设,其促进NMDA受体的NR 1亚基的磷酸化并增强神经性疼痛中NMDA介导的突触传递。本申请的具体目的是(1)定义CK 2和CK 3之间不平衡的作用,(磷酸化)和钙调神经磷酸酶(2)确定神经损伤后脊髓中CK 2活性水平及其在NMDA受体NR 1亚基磷酸化增加中的作用;以及(3)确定NR 1和CK 2亚基之间的蛋白质相互作用、NMDA受体上的CK 2磷酸化位点以及它们在神经病理性疼痛中NMDA受体活性增加的调节中的作用。CK 2在神经损伤诱导的脊髓突触可塑性发育中的作用以前未被认识。我们希望,新的发现,从这个建议将是至关重要的,不仅显着提高我们的理解神经性疼痛的分子机制,但也发展新的战略来治疗神经性疼痛。由于直接阻断NMDA受体会产生不可耐受的副作用,因此靶向CK 2及其特异性NMDA受体磷酸化位点可能是降低NMDA受体活性和神经性疼痛的新策略。
项目成果
期刊论文数量(10)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Chloride Homeostasis Critically Regulates Synaptic NMDA Receptor Activity in Neuropathic Pain.
- DOI:10.1016/j.celrep.2016.04.039
- 发表时间:2016-05-17
- 期刊:
- 影响因子:8.8
- 作者:Li L;Chen SR;Chen H;Wen L;Hittelman WN;Xie JD;Pan HL
- 通讯作者:Pan HL
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Hui-Lin Pan其他文献
Hui-Lin Pan的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Hui-Lin Pan', 18)}}的其他基金
Neural Mechanisms of Calcineurin Inhibitor-Induced Hypertension
钙调神经磷酸酶抑制剂诱发高血压的神经机制
- 批准号:
10669034 - 财政年份:2020
- 资助金额:
$ 35.52万 - 项目类别:
Neural Mechanisms of Calcineurin Inhibitor-Induced Hypertension
钙调神经磷酸酶抑制剂诱发高血压的神经机制
- 批准号:
10457895 - 财政年份:2020
- 资助金额:
$ 35.52万 - 项目类别:
Neural Mechanisms of Calcineurin Inhibitor-Induced Hypertension
钙调神经磷酸酶抑制剂诱发高血压的神经机制
- 批准号:
10224340 - 财政年份:2020
- 资助金额:
$ 35.52万 - 项目类别:
Signaling Mechanisms of Opioid-Induced Hyperalgesia and Tolerance
阿片类药物引起的痛觉过敏和耐受性的信号机制
- 批准号:
9251088 - 财政年份:2017
- 资助金额:
$ 35.52万 - 项目类别:
Neuronal Plasticity and Signaling in Neuropathic Pain
神经病理性疼痛中的神经元可塑性和信号传导
- 批准号:
8021606 - 财政年份:2011
- 资助金额:
$ 35.52万 - 项目类别:
Neuronal Plasticity and Signaling in Neuropathic Pain
神经病理性疼痛中的神经元可塑性和信号传导
- 批准号:
8241913 - 财政年份:2011
- 资助金额:
$ 35.52万 - 项目类别:
Neuronal Plasticity and Signaling in Neuropathic Pain
神经病理性疼痛中的神经元可塑性和信号传导
- 批准号:
8640990 - 财政年份:2011
- 资助金额:
$ 35.52万 - 项目类别:
Neuronal Plasticity and Signaling in Neuropathic Pain
神经病理性疼痛中的神经元可塑性和信号传导
- 批准号:
8443851 - 财政年份:2011
- 资助金额:
$ 35.52万 - 项目类别:
Synaptic mechanisms regulating sympathetic drive
调节交感神经驱动的突触机制
- 批准号:
8692568 - 财政年份:2005
- 资助金额:
$ 35.52万 - 项目类别:
Synaptic Mechanisms Regulating Sympathetic Drive
调节交感神经驱动的突触机制
- 批准号:
7056798 - 财政年份:2005
- 资助金额:
$ 35.52万 - 项目类别:
相似海外基金
Planning Study for the Development of Sigma 2 ligands as Analgesics
Sigma 2 配体镇痛药开发规划研究
- 批准号:
10641500 - 财政年份:2023
- 资助金额:
$ 35.52万 - 项目类别:
Designing and validating optimal nonaddictive analgesics using the CANDO paradigm
使用 CANDO 范式设计和验证最佳的非成瘾性镇痛药
- 批准号:
10485593 - 财政年份:2023
- 资助金额:
$ 35.52万 - 项目类别:
Identification of botanical hHv1 channel blockers as analgesics for neuropathic pain
植物 hHv1 通道阻滞剂作为神经性疼痛镇痛药的鉴定
- 批准号:
10728526 - 财政年份:2023
- 资助金额:
$ 35.52万 - 项目类别:
Development of LPA5 Antagonists as Analgesics
LPA5 拮抗剂镇痛药的开发
- 批准号:
10638278 - 财政年份:2023
- 资助金额:
$ 35.52万 - 项目类别:
Designed Multiple Ligands as Non-opioid Analgesics for Treating Chronic Pain
设计多种配体作为非阿片类镇痛药,用于治疗慢性疼痛
- 批准号:
10621646 - 财政年份:2023
- 资助金额:
$ 35.52万 - 项目类别:
Elucidation of the mechanism of pain suppression by exercise and development of new analgesics
阐明运动镇痛机制及开发新型镇痛药
- 批准号:
22K19602 - 财政年份:2022
- 资助金额:
$ 35.52万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
Single-administration microneedles with controlled sustained release of non-opioid analgesics to treat osteoarthritis pain
单次给药微针控制缓释非阿片类镇痛药治疗骨关节炎疼痛
- 批准号:
10425794 - 财政年份:2022
- 资助金额:
$ 35.52万 - 项目类别:
Allosteric Targeting of Cannabinoid CB1 Receptor to Develop Non-Addictive Small Molecule Analgesics
大麻素 CB1 受体变构靶向开发非成瘾性小分子镇痛药
- 批准号:
10512672 - 财政年份:2022
- 资助金额:
$ 35.52万 - 项目类别:
A novel clinically-relevant mouse model of chronic overlapping pain conditions for screening analgesics
用于筛选镇痛药的新型临床相关慢性重叠疼痛小鼠模型
- 批准号:
10821681 - 财政年份:2022
- 资助金额:
$ 35.52万 - 项目类别:
Single-administration microneedles with controlled sustained release of non-opioid analgesics to treat osteoarthritis pain
单次给药微针控制缓释非阿片类镇痛药治疗骨关节炎疼痛
- 批准号:
10721752 - 财政年份:2022
- 资助金额:
$ 35.52万 - 项目类别:














{{item.name}}会员




